help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakanishi, T.
Right arrow Articles by Tanaka, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakanishi, T.
Right arrow Articles by Tanaka, K.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CHORIONIC GONADOTROPIN
*TIN COMPOUNDS
*TRI-N-BUTYLTIN HYDRIDE
Medline Plus Health Information
*High Risk Pregnancy
The Journal of Clinical Endocrinology & Metabolism Vol. 87, No. 6 2830-2837
Copyright © 2002 by The Endocrine Society


Other Original Articles

Trialkyltin Compounds Enhance Human CG Secretion and Aromatase Activity in Human Placental Choriocarcinoma Cells

Tsuyoshi Nakanishi, Junya Kohroki, Shizuko Suzuki, Junichi Ishizaki, Youhei Hiromori, Shinri Takasuga, Norio Itoh, Yoshiteru Watanabe, Naoki Utoguchi and Keiichi Tanaka

Department of Toxicology (T.N., J.K., S.S., I.J., Y.H., S.T., N.I., K.T.), Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan; and Department of Pharmaceutics (Y.W., N.U.), Showa Pharmaceutical University, Tokyo 194-8543, Japan

Address all correspondence and requests for reprints to: Tsuyoshi Nakanishi, Ph.D., Department of Toxicology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6, Yamadaoka Suita, Osaka 565-0871, Japan. E-mail: . nakanishi{at}phs.osaka-u.ac.jp

Abstract

Human choriocarcinoma cell lines have been used as placental models for the study of endocrine function, including aromatase (CYP19) activity and the secretion of human CG (hCG). In the present study, we investigated the effects of trialkyltin compounds, which are suspected endocrine disrupters, on aromatase activity and hCG secretion in human choriocarcinoma JAR, JEG-3, and BeWo cells. Protein synthesis as measured by 35S-methionine incorporation in all cell lines was markedly decreased by treatment with both tributyltin (TBT) and triphenyltin (TPT) at concentrations above 3 x 10-7 M, due to cytotoxicity. In JAR cells, 35S-methionine uptake was decreased by 50% at 3 x 10-7 M of TBT. At a TPT concentration of 1 x 10-7 M, protein synthesis in JAR cells was not affected, whereas JEG-3 and BeWo cells demonstrated slightly decreases. In all cell lines, both TBT and TPT increased levels of hCG secretion and aromatase activity in a dose- and time-dependent fashion following exposure to nontoxic concentration ranges. In addition, these trialkyltin compounds enhanced 8-bromo-cAMP-induced hCG secretion and aromatase activity in JAR cells. TBT caused dose-related increases in steady-state mRNA levels of both hCGß and CYP19 in JAR cells following 24- or 48-h exposure to nontoxic concentrations of TBT. However, these mRNA changes in JAR cells were not comparable to the changes in both hCG secretion and aromatase activity. These results indicate that the observed trialkyltin-induced alterations in human choriocarcinoma cells are due to other mechanism in addition to a regulation of hCG and CYP19 mRNA levels. Our studies suggest that trialkyltin compounds are potent stimulators of human placental hCG production and aromatase activity in vitro; and the placenta represents a potential target organ for trialkyltin compounds, whose endocrine-disrupting effects might be the result of local changes in hCG and estrogen concentrations in pregnant women.




This article has been cited by other articles:


Home page
EndocrinologyHome page
X. Wu, T. Iguchi, N. Itoh, K. Okamoto, T. Takagi, K. Tanaka, and T. Nakanishi
Ascorbic Acid Transported by Sodium-Dependent Vitamin C Transporter 2 Stimulates Steroidogenesis in Human Choriocarcinoma Cells
Endocrinology, January 1, 2008; 149(1): 73 - 83.
[Abstract] [Full Text] [PDF]


Home page
Toxicol Ind HealthHome page
A. Hoth, R. Johannisson, S. S. Ali, J. Schulze, and C.-P. Siegers
Cytotoxicity of organotin compounds in different cultured cell lines
Toxicology and Industrial Health, April 1, 2005; 21(3-4): 131 - 136.
[Abstract] [PDF]


Home page
Mol. Pharmacol.Home page
T. Kanayama, N. Kobayashi, S. Mamiya, T. Nakanishi, and J.-i. Nishikawa
Organotin Compounds Promote Adipocyte Differentiation as Agonists of the Peroxisome Proliferator-Activated Receptor {gamma}/Retinoid X Receptor Pathway
Mol. Pharmacol., March 1, 2005; 67(3): 766 - 774.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
A. Adeeko, D. Li, D. S. Forsyth, V. Casey, G. M. Cooke, J. Barthelemy, D. G. Cyr, J. M. Trasler, B. Robaire, and B. F. Hales
Effects of in Utero Tributyltin Chloride Exposure in the Rat on Pregnancy Outcome
Toxicol. Sci., August 1, 2003; 74(2): 407 - 415.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society